NEW YORK (GenomeWeb News) — The National Cancer Institute has given Rules-Based Medicine a $1.1 million Phase I/Phase II Small Business Innovation Research contract to develop immunoassays for cancer, the biomarker testing company said today.
 
Austin, Texas-based RBM said it will use the cash to develop 50 new quantitative, multiplexed immunoassays for cancer-related proteins to add to its Human Multi-Analyte Profile platform.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.